Study of Outcome of Children Previously Enrolled in European Trials of Treatment for Primitive Neuroectodermal Tumour (PNET)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain and Central Nervous System Tumors
- Sponsor
- Children's Cancer and Leukaemia Group
- Locations
- 20
- Primary Endpoint
- Quality of life (QOL) as measured by QOL questionnaire
- Last Updated
- 12 years ago
Overview
Brief Summary
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients with primitive neuroectodermal tumors.
PURPOSE: This phase III trial is studying quality of life in patients who have undergone previous treatment for primitive neuroectodermal tumors.
Detailed Description
OBJECTIVES: Primary * Determine the quality of survival of patients in the UK and other European countries enrolled in previous International Society of Pediatric Oncology (SIOP) 2 or 3 phase III trials for treatment of pediatric primitive neuroectodermal tumors (PNET). * Compare the quality of survival between children allocated to different treatments in these trials. Secondary * Determine the framework that will allow similar information to be collected across all participating countries in the PNET 4 trial that opened in autumn 2002. OUTLINE: This is a cross-sectional, multicenter study. Pediatric oncologists, teachers, patients ≥ 12 years old, and parents of children age 3-11 years old complete six questionnaires to assess the patients' motor and sensory function, cognition, behavior, emotion, educational provision and achievement, social integration, and the subjective experience of the patients and their families. PROJECTED ACCRUAL: A total of 229 patients will be accrued for this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Quality of life (QOL) as measured by QOL questionnaire
Secondary Outcomes
- Quality of survival compared among children undergoing different treatments by Health Utilities Index